Updated on 2 May 2016
Israel's fully-integrated biopharmaceutical company MediWound has signed an agreement granting Japan's Kaken Pharmaceuticals Co Ltd exclusive rights to develop and distribute NexoBrid in Japan for the treatment of severe burns.
Sales of NexoBrid in Japan will commence after Kaken completes the local research and development requirements and obtains local regulatory approval from the Japanese Ministry of Health, Labour and Welfare (MHLW), which are expected to be granted within two years, or possibly longer.
NexoBrid is an easy-to-use, topically-applied product that removes dead or damaged tissue, known as eschar, in approximately four hours without harming the surrounding healthy tissues.
"We are particularly pleased to partner with Kaken for the development and distribution of NexoBrid in Japan as they share our commitment to improving quality-of-life by bringing superior pharmaceuticals to address patients' needs. Kaken has nearly 70 years of experience in the Japanese pharmaceuticals market, strong local presence and a history of partnering with leading pharmaceutical companies. The introduction of NexoBrid in Japan will provide burn specialists with a new minimally invasive treatment for severe burns, that significantly decreases surgical excision and grafting, leading to reduction in the long-term incidence of scarring in severe burn patients," stated Gal Cohen, President and Chief Executive Officer of MediWound. "We look forward to working closely with Kaken towards a successful market entry in this important market."